semaglutide and liver damage treats disease in two thirds of patients How a drug for diabetes

Photoaffinity labelling by S-(p-azidophenacyl)-glutathione of glyoxalase II and [PMID: 7417267] Laboratory literature summary: Photoaffinity labelling by S-(p-azidophenacyl)-glutathione of glyoxalase II and glutathione S-transferase

Well, lets focus on that

Copper peptides are generally safe for most people when used topically, as they don't enter the body to produce systemic effects, but copper peptides might not be appropriate for people with a known allergy or sensitivity to copper

AD is the most common cause of dementia which is characterized by progressive cognitive decline and neurodegeneration

Semaglutide (also injected weekly) was associated with an average weight loss of around 11% after 24 to 68 weeks, with evidence suggesting the effect can persist for up to two years, based on 18 randomized controlled trials (27 949 participants)